Noden Pharma Drug Patent Portfolio

Noden Pharma owns 3 orange book drugs protected by 18 US patents Given below is the list of Noden Pharma's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10016407 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10149843 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10231961 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10413505 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10420760 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10857095 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10894012 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10933060 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10973811 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US10987347 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US11040032 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US9867815 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
Active
US8618172 Galenical formulations of organic compounds 13 Jul, 2028
Active
US8617595 Galenic formulations of organic compounds 19 Aug, 2026
Active
US8617595 Galenic formulations of organic compounds 19 Feb, 2026
Active
US9023893 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases 03 Mar, 2022 Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jan, 2019 Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Noden Pharma.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jul, 2024 US10894012
Payment of Maintenance Fee, 4th Year, Large Entity 22 May, 2024 US10857095
Expire Patent 12 Jun, 2023 US9023893
Payment of Maintenance Fee, 4th Year, Large Entity 08 Mar, 2023 US10420760 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 01 Mar, 2023 US10413505
Maintenance Fee Reminder Mailed 26 Dec, 2022 US9023893
Payment of Maintenance Fee, 4th Year, Large Entity 14 Sep, 2022 US10231961
Payment of Maintenance Fee, 4th Year, Large Entity 13 Jun, 2022 US10016407 (Litigated)
Surcharge for Late Payment, Large Entity 13 Jun, 2022 US10016407 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 09 Jun, 2022 US10149843
Maintenance Fee Reminder Mailed 28 Feb, 2022 US10016407 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 14 Jan, 2022 US9867815 (Litigated)
Surcharge for Late Payment, Large Entity 14 Jan, 2022 US9867815 (Litigated)
Maintenance Fee Reminder Mailed 06 Sep, 2021 US9867815 (Litigated)
Patent Issue Date Used in PTA Calculation 22 Jun, 2021 US11040032


Noden Pharma Drug Patents' Oppositions Filed in EPO

Noden Pharma drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 04, 2009, by Teva Pharmaceuticals Industries Ltd.. This opposition was filed on patent number EP05015603A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP08002401A Apr, 2014 STADA Arzneimittel AG Revoked
EP05015603A Mar, 2009 Ratiopharm GmbH Revoked
EP05015603A Feb, 2009 TEVA PHARMACEUTICALS INDUSTRIES LTD. Revoked


Noden Pharma's Family Patents

Noden Pharma drugs have patent protection in a total of 39 countries. It's US patent count contributes only to 16.2% of its total global patent coverage. 18 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Noden Pharma Drug List

Given below is the complete list of Noden Pharma's drugs and the patents protecting them.


1. Goprelto

Goprelto is protected by 12 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10016407 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10149843 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10231961 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10413505 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10420760 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10857095 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10894012 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10933060 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10973811 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US10987347 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US11040032 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active
US9867815 Pharmaceutical compositions and methods of using the same 07 Feb, 2037
(12 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Goprelto's drug page


2. Tekturna

Tekturna is protected by 4 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8617595
(Pediatric)
Galenic formulations of organic compounds 19 Aug, 2026
(1 year, 10 months from now)
Active
US8617595 Galenic formulations of organic compounds 19 Feb, 2026
(1 year, 4 months from now)
Active
US5559111
(Pediatric)
δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jan, 2019
(5 years ago)
Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekturna's drug page


3. Tekturna Hct

Tekturna Hct is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8618172 Galenical formulations of organic compounds 13 Jul, 2028
(3 years from now)
Active
US9023893 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases 03 Mar, 2022
(2 years ago)
Expired
US5559111
(Pediatric)
δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jan, 2019
(5 years ago)
Expired
US5559111 δ-amino-γ-hydroxy-ω-aryl-alkanoic acid amides 21 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tekturna Hct's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List